Indirect Modulation of Dopamine D 2 Receptors as Potential Pharmacotherapy for Schizophrenia: I. Adenosine Agonists

Abstract

Spanish

French

OBJECTIVE:

To review preclinical and clinical information related to pharmacologic modulation of dopamine D₂ receptors as potential novel antipsychotic therapy. Specifically, to summarize the data that suggest a modulatory action of adenosine A_2A receptors on dopamine D₂ receptors and, therefore, a possible rational role of adenosine A_2A agonists as novel antipsychotic agents.

DATA SOURCES:

Primary and review articles were identified by MEDLINE search (from 1966 to May 1998) and through secondary sources.

STUDY SELECTION AND DATA EXTRACTION:

All of the articles identified from the data sources were evaluated and all information deemed relevant was included in this review.

DATA SYNTHESIS:

For all of the older and many of the newer antipsychotic agents, there is a strong correlation between clinical antipsychotic activity and affinity for dopamine D₂ receptors. Unfortunately, dopamine D₂ receptors are believed to also be involved in the adverse effect profile of these agents. The indirect modulation of dopamine D₂ receptors, rather than direct block, might produce antipsychotic effects without the usual adverse reactions. Several lines of evidence from animal studies suggest that the use of selective A_2A agonists might represent a novel approach to the treatment of psychoses.

CONCLUSIONS:

Dopamine receptor modulation might represent a novel antipsychotic approach or adjunct therapy. The data regarding adenosine agonists (particularly selective A_2A receptor agonists) are inconclusive at the present time. Direct clinical demonstration of effectiveness is required.

Keywords

adenosine receptors antipsychotics schizophrenia

Get full access to this article

View all access options for this article.

References

Seeman

. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987;1: 133–52.

Potter

Hollister

. Antipsychotic agents & lithium. In: Katzung

, ed. Basic & clinical pharmacology. 7th ed. Stamford, CT: Appleton and Lange, 1998: 464–82.

Crismon

Dorson

. Schizophrenia. In: Dipiro

Talbert

Yee

Matzke

Wells

Posey

, eds. Pharmacotherapy, a pathological approach. 3rd ed. Stamford, CT: Appleton and Lange, 1997: 1367–9.

Schizophrenia and other psychotic disorders. In: Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994: 273–315.

Gottesman II . Schizophrenia genesis: the origins of madness. New York: WH Freeman and Co., 1991: 1–9.

Jeste

del Carmen

Lohr

Wyatt

. Did schizophrenia exist before the eighteenth century? Comp Psychiatry 1985;26: 493–503.

Hare

. Schizophrenia as a recent disease. Br J Psychiatry 1988;153: 521–31.

Bark

. On the history of schizophrenia: Evidence of its existence before 1800. N Y State J Med 1988;88: 374–83.

Cooper

Sartorius

. Cultural and temporal variation in schizophrenia: A speculation on the importance of industrialization. Br J Psychiatry 1977;130: 50–5.

10.

Hare

. Was insanity on the increase? The fifty-sixth Maudsley Lecture. Br J Psychiatry 1983;142: 439–55.

11.

Bleuler

. Die prognose der dementia praecox (schizophreniegruppe). Allgemeine Z fur Psychiatr 1908;65: 436–64.

12.

Torrey

Bowler

Taylor

Gottesman II . Schizophrenia and manic—depressive disorder. New York: Basic Books, 1994: 86–9.

13.

Hyde

Casanova

Kleinman

Weinberger

. Neuroanatomical and neurochemical pathology in schizophrenia. In: Tasman

Goldfinger

, eds. Review of psychiatry. Vol 10. Washington, DC: American Psychiatric Association Press, 1991: 7–23.

14.

Yolken

Torrey

. Viruses, schizophrenia, and bipolar disorder. Clin Microbiol Rev 1995;8: 131–45.

15.

Fernandez

Hewicker

Trautwein

Pohlenz

Liess

. Viral antigen distribution in the central nervous system of cattle persistently infected with bovine viral diarrhea virus. Vet Pathol 1989;26: 26–32.

16.

Nieuwenhuys

. Chemoarchitecture of the brain. Berlin: Springer-Verlag, 1985: 14–9.

17.

Weinberger

. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987;44: 660–9.

18.

Johansson

Fredholm

. Further characterization of the binding of the adenosine receptor agonist, [3H]CGS 21680 to rat brain using autoradiography. Neuropharmacology 1995;34: 393–403.

19.

Cunha

Johansson

Constantino

Sabastião

Fredholm

. Evidence for high-affinity binding sites for the adenosine A_2a receptor agonist [3H] CGS 21680 in the rat hippocampus and cerebral cortex that are different from striatal A_2a . Naunyn Schmiedebergs Arch Pharmacol 1996;353: 261–71.

20.

Fuxe

Agnati

von Euler

Tanganelli

O'Connor

Ferr

Neuropeptides, excitatory amino acid and adenosine A₂ receptors regulate D₂ receptors via intramembrane receptor-receptor interactions: relevance for Parkinson's disease and schizophrenia. Neurochem Int 1992;20 (suppl):215S–24S.

21.

Ferré

. Adenosine-dopamine interactions in the ventral striatum: Implications for the treatment of schizophrenia. Psychopharmacology 1997;133: 107–20.

22.

Watson

Arkinstall

. The G-protein linked receptor factsbook London: Academic Press, 1994: 19–31.

23.

Olah

Stiles

. Adenosine receptor subtypes: Characterization and therapeutic regulation. Annu Rev Pharmacol Toxicol 1995;35: 581–606.

24.

Jarvis

Williams

. Direct autoradiographic localization of A₂ receptors in the rat brain using the A_2a selective[3H] CGS 21680. Eur J Pharmacol 1989;168: 243–6.

25.

Wan

Sutherland

Geiger

. Binding of the adenosine A₂ receptor ligand [3H]CGS 21680 to human and rat brain: evidence for multiple affinity sites. J Neurochem 1990;55: 1763–71.

26.

James

Xuereb

Askalan

Richardson

. Adenosine receptors in postmortem human brain. Br J Pharmacol 1992;105: 238–44.

27.

Cunha

Johansson

Van der Ploeg

Sebastião

Ribeiro

Fredholm

. Evidence for functionally important adenosine A₂ receptors in the rat hippocampus. Brain Res 1994;649: 208–16.

28.

Mahan

McVittie

Smyk-Randall

Nakata

Monsma

Jr Gerfen

Cloning and expression of an A₁ adenosine receptor from rat brain. Mol Pharmacol 1991;40:1–7.

29.

Fink

Weaver

Rivkees

Peterfreund

Pollack

Adler

Molecular cloning of the rat A₂ adenosine receptor: selective co-expression with D₂ dopamine receptors in rat striatum. Mol Brain Res 1992;14:186–95.

30.

Maenhaut

van Sande

Libert

Abramowicz

Parmentier

Vanderhaeghen

J-J

RDC8 codes for an adenosine A₂ receptor with psychological constitutive activity. Biochem Biophys Res Commun 1990;173:1169–78.

31.

Zhou

Q-Y

Olah

Johnson

Stiles

Civelli

. Molecular cloning and characterization of an adenosine receptor: The A3 adenosine receptor. Proc Natl Acad Sci U S A 1992;89: 7432–6.

32.

Schwabe

Fein

Lorenzen

. Pharmacological properties of adenosine receptors and adenosine binding proteins. Drug Dev Res 1993;28: 220–5.

33.

Schiffmann

Halleux

Vanderhaeghen

J-J

. Adenosine A_2a receptor expression in striatal neurons: implications for basal ganglia pathophysiology. Drug Dev Res 1993;28: 381–5.

34.

Sebastião

Stone

Ribeiro

. The inhibitory adenosine receptor at the neuromuscular junction and hippocampus of the rat: Antagonism by 1,3,8-substituted xanthines. Br J Pharmacol 1990;101: 453–9.

35.

Sebastião

Ribeiro

. Evidence for the presence of excitatory A₂ adenosine receptors in the rat hippocampus. Neurosci Letts 1992;138: 41–4.

36.

Cunha

Constantino

Sebastião

Ribeiro

. Modification of A₁ and A_2a adenosine receptor binding in aged striatum, hippocampus and cortex of the rat. NeuroReport 1995;6: 1583–8.

37.

Abbracchio

Fogliatto

Paoletti

Rovati

Cattabeni

. Prolonged in vitro exposure of rat brain slices to adenosine analogues: Selective desensitization of A₁ but not A₂ receptors. Eur J Pharmacol 1992;227: 317–24.

38.

Phillis

. Evidence for an A₂-like adenosine receptor on cerebral cortical neurons. J Pharmacol Exp Ther 1982;34: 453–4.

39.

Stone

. Purine receptors involved in the depression of neuronal firing in cerebral cortex. Brain Res 1982;248: 367–70.

40.

Phillis

. The selective A₂ agonist, CGS 21680, is a potent depressant of cerebral cortical neuronal activity. Brain Res 1990;509: 328–30.

41.

Lin

Phillis

. Characterization of the depression of rat cerebral cortical neurons by selective adenosine agonists. Brain Res 1991;540: 307–10.

42.

Sebastião

Ribeiro

. Adenosine A₂ receptor-mediated excitatory actions on the nervous system. Prog in Neurobiol 1996;48: 167–89.

43.

Brown

James

Reddington

Richardson

. Both A₁ and A_2a purine receptors regulate striatal acetylcholine release. J Neurochem 1990;55: 31–8.

44.

Spignoli

Pedata

Pepeu

. A₁ and A₂ adenosine receptors modulate acetylcholine release from brain slices. Eur J Pharmacol 1984;97: 341–2.

45.

DiIorio

Ballerini

Ciccarelli

DiMuzio

Traversa

Caciagli

. A₁ and A₂ adenosine receptors' involvement in controlling purine and acetylcholine release from rat hippocampal slices. Nucleos Nucleot 1991;10: 1237–8.

46.

Correia-De-Sá

Ribeiro

. Tonic A_2a receptor activation modulates nicotinic autoreceptor function at the rat neuromuscular junction. Eur J Pharmacol 1994;271: 349–55.

47.

Kirkpatrick

Richardson

. Adenosine receptor-mediated modulation of acetylcholine release from rat striatal synaptosomes. Br J Pharmacol 1993;110: 949–54.

48.

Cunha

Johansson

Fredholm

Ribeiro

Sebastião

. Adenosine A_2a receptors stimulate acetylcholine release from nerve terminals of the rat hippocampus. Neurosci Letts 1995;196: 41–4.

49.

Mayfield

Suzuki

Zahniser

. Adenosine A_2A receptor modulation of electrically evoked endogenous GABA release from slices of rat globus pallidus. J Neurochem 1993;60: 2334–7.

50.

Mayfield

Larson

Orona

Zahniser

. Opposing action of adenosine A_2A and dopamine D₂ receptor activation on GABA release in the basal ganglia: evidence for an A_2A/D₂ receptor interaction in globus pallidus. Synapse 1996;22: 132–8.

51.

Kirk

Richardson

. Adenosine A_2A receptor-mediated modulation of striatal [3H]GABA [3H]acetylcholine release. J Neurochem 1994;62: 960–6.

52.

Kurokawa

Kirk

Kirkpatrick

Kase

Richardson

. Inhibition by KF17837 of adenosine A_2A receptor-mediated modulation of striatal GABA and acetylcholine release. Br J Pharmacol 1994;113: 43–8.

53.

O'Regan

Simpson

Perkins

Phillis

. The selective A₂ agonist CGS 21680 enhances excitatory transmitter amino acid release from the ischemic rat cerebral cortex. Neurosci Letts 1992;138: 169–72.

54.

Okada

Nishimura

Miyamoto

. Excitatory effect of adenosine on neurotransmission in the slices of superior colliculus and hippocampus of guinea pig. Neurosci Letts 1992;120: 205–8.

55.

Gonçalves

Queiroz

. Facilatory and inhibitory modulation of endogenous adenosine of noradrenaline release in the epididymal portion of the rat vas deferens. Nauyn-Schmied Arch Pharmacol 1993;348: 367–71.

56.

Koizumi

Watano

Nakazawa

Inoue

. Potentiation by adenosine of ATP-evoked dopamine release via a pertussis-sensitive mechanism in rat phaeochromocytoma PC12 cells. Br J Pharmacol 1994;112: 992–7.

57.

Zetterström

Fillenz

. Adenosine agonists can both inhibit and enhance in vivo striatal dopamine release. Eur J Pharmacol 1990;180: 137–43.

58.

Ongini

Fredholm

. Pharmacology of adenosine A_2A receptors. Trends Pharmacol Sci 1996;17: 364–72.

59.

Ferré

O'Connor

Snaprud

Ungerstedt

Fuxe

. Antagonistic interaction between adenosine A_2A receptors and dopamine D₂ receptors in the ventral striopallidal system: implications for the treatment of schizophrenia. Neurosci 1994;63: 765–73.

60.

Daly

. Adenosine receptors: Targets for future drugs. J Med Chem 1982;25: 197–207.

61.

Bridges

Moos

Szotek

Trivedi

Bristol

Heffner

N₆-(2−2-Diphenylethyl)-adenosine, a novel adenosine receptor agonist with antipsychotic-like activity. J Med Chem 1987;30:1709–11.

62.

Mayo

Falkowski

Jones

. Caffeine: Use and effects in long-stay psychiatric patients. Br J Psychiatry 1993;162: 543–5.

63.

Honigfeld

Klett

. The nurses' observation scale for in-patient evaluation — a new scale for measuring improvement in chronic schizophrenia. J Clin Psychol 1965;21: 65–71.

64.

Snaith

Baugh

Clayden

Husain

Sipple

. The Clinical Anxiety Scale: An instrument derived from the Hamilton Anxiety Scale. Br J Psychiatry 1982;141: 518–23.

65.

Montgomery

Asberg

. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134: 382–9.

66.

Overall

Gorham

. The brief psychiatric rating scale. Psychol Rep 1962;10: 799–812.

67.

Koczapski

Paredes

Kogan

Ledwidge

Higenbottam

. Effects of caffeine on behavior of schizophrenic inpatients. Schizophr Bull 1989;15: 339–44.

68.

Lucas

Pickar

Kelsoe

Rapaport

Pato

Hommer

. Effects of the acute administration of caffeine in patients with schizophrenia. Biol Psychiatry 1990;28: 35–40.

69.

Bunney

Hamberg

. Methods for reliable longitudinal observation of behavior. Arch Gen Psychiatry 1963;9: 280–94.

70.

Mathew

Wilson

Tant

. Caffeine-induced cerebral blood flow changes in schizophrenia. Eur Arch Psychiatry Neurol Sci 1986;235: 206–9.

71.

Dalby

Williams

. Caffeine use by psychiatric patients. Ir J Psychol Med 1989;6: 103–5.

72.

Clementz

Dailey

. Psychotropic effects of caffeine. Am Fam Physician 1988;37: 167–72.

73.

Gilliland

Bullock

. Caffeine: A potential drug of abuse. Adv Alcohol Subs Abuse 1983–84;3: 53–73.

74.

Sawyer

Julia

Turin

. Caffeine and human behavior: Arousal, anxiety, and performance effects. J Behav Med 1982;5: 415–39.

75.

Mackay

Rollins

. Caffeine and caffeinism. J R Nav Med Serv 1989;75: 65–7.

76.

Victor

Lubetsky

Greden

. Somatic manifestations of caffeinism. J Clin Psychiatry 1981;42: 185–8.

77.

Greden

Fontaine

Lubetsky

Chamberlin

. Anxiety and depression associated with caffeinism among psychiatric inpatients. Am J Psychiatry 1978;135: 963–6.

78.

Rapoport

Elkins

Neims

Zahn

Berg

. Behavioral and autonomic effects of caffeine in normal boys. Dev Pharmacol Ther 1981;3: 74–82.

79.

Karayiorgou

Morris

Morrow

Shprintzen

Goldbert

Borrow

Schizophrenia susceptibility associated with interstitial deletions of chromosome 22q11. Proc Natl Acad Sci U S A 1995;92:7612–6.

80.

Coon

Holik

Hoff

Reimherr

Wender

Myles-Worsley

Analysis of chromosome 22 markers in nine schizophrenia pedigrees. Am J Med Genet 1994;54:72–9.

81.

Pulver

Karayiorgou

Wolyniec

Lasseter

Kasch

Nestadt

Sequential strategy to identify a susceptibility gene for schizophrenia: Report of potential linkage on chromosome 22q12-q13.1: Part 1. Am J Med Genet 1994;54: 36–43.

82.

Schwab

Lerer

Albus

Maier

Hallmayer

Fimmers

Potential linkage for schizophrenia on chromosome 22q12–13: A replication study. Am J Med Genet 1995;60:436–43.

83.

Vallada

Gill

Sham

Lim

LCC

Nanko

Asherson

Linkage studies on chromosome 22 in familial schizophrenia. Am J Med Genet 1995;60:139–46.

84.

Deckert

Nöthen

Bryant

Schuffenhauer

Schofield

Spurr

Mapping of the human adenosine A_2a receptor gene: relationship to potential schizophrenia loci on chromosome 22q and exclusion from the CATCH 22 region. Hum Genet 1997;99:326–8.

85.

Kruglyak

Lander

. High resolution genetic mapping of complex traits. Am J Hum Genet 1995;56: 1212–23.

86.

Deckert

Nöthen

Rietschel

Wildenauer

Bondy

Ertl

Human adenosine A_2a receptor (A_2aAR) gene: systematic mutation screening in patients with schizophrenia. J Neural Transm 1996;103:1447–55.

87.

Orita

Suzuki

Sekiya

Hayashi

. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 1989;5: 874–9.

88.

Martin

Rossi

Jarvis

. Adenosine agonists reduce conditioned avoidance responding in the rat. Pharmacol Biochem Behav 1993;45: 951–8.

89.

Arnt

. Pharmacological specificity of conditioned avoidance response inhibition in rats: Inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol Toxicol 1982;51: 321–9.

90.

Kuribara

Tadokoro

. Correlation between antiavoidance activities and antipsychotic drugs in rats and daily clinical dose. Pharmacol Biochem Behav 1981;14: 181–92.

91.

Kafka

Corbett

. Selective adenosine A_2A receptor/dopamine D₂ receptor interactions in animal models of schizophrenia. Eur J Pharmacol 1996;295: 147–54.

92.

Ferré

Popoli

Giménez-Llort

Finnman

Martìnez

de Carolis

A Scotti

Postsynaptic antagonistic interaction between adenosine A₁ and dopamine D₁ receptors. NeuroReport 1994;6:73–6.

93.

Ferré

Snaprud

Schwarz

Ögren

Fuxe

. Chronic haloperidol treatment leads to an increase in the intramembrane interaction between adenosine A₂ and dopamine D₂ receptors in the neostriatum. Psychopharmacol Bull 1994;116: 279–84.

94.

Parsons

Togasaki

Kassir

Przedborski

. Neuroleptics up-regulate adenosine A_2a receptors in rat striatum: implications for the mechanism and the treatment of tardive dyskinesia. J Neurochem 1995;65: 2057–64.